Merck

Last updated January 31, 2026

124

Innovation Areas

5,362

Inventors

Collaborations

Fused azole dgat2 inhibitors: MerckRecent Research Landscape

Metabolic disorders arise from dysregulated triglyceride synthesis, which is mitigated by engineering specific heterocyclic scaffolds to selectively block diacylglycerol O-acyltransferase 2 activity. These molecular structures provide the precise chemical control necessary to modulate lipid metabolism without off-target effects.

What technical problems is Merck addressing in Fused azole dgat2 inhibitors?

Excessive hepatic triglyceride accumulation

(9)evidences

Abnormal lipid deposition leads to metabolic dysfunction and liver damage. Reducing triglyceride synthesis prevents disease progression and metabolic syndrome complications.

Impaired systemic glucose regulation

(2)evidences

Excessive triglyceride accumulation and impaired glucose homeostasis. Mitigating these conditions prevents chronic metabolic diseases and organ dysfunction.